Profile: Actavis PLC (ACT)
3 Dec 2013
Actavis PLC, incorporated on May 16, 2013, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes. The Company's product formulations include modified release, solid oral dosage, semi-solids, suspensions, transdermals, suppositories, creams, ointments, liquids and injectables. In October 2013, Actavis Inc acquired Warner Chilcott PLC and in connection with the acquisition, Actavis Inc and Warner Chilcott PLC have been combined under a new company, Actavis PLC.
The Company’s Actavis Pharma business manufactures, markets and distributes products therapeutic categories, which include Antibiotics, Anti-inflammatories, Cardiovascular Diseases, Dermatology Products, Central Nervous System Disorders, Metabolic Disorders, Musculo-skeletal System Disorders, Respiratory System Treatments and Contraceptives. Actavis Specialty Brands is the Company’s global branded specialty pharmaceutical business focused in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories. Actavis Specialty Brands also has a portfolio of five biosimilar products in development in Women's Health and Oncology.
1 Grand Canal Square
Docklands, Dublin 2